Which hypersensitivity type is involved in myasthenia gravis?

Study for the NBME Immunology Test. Study with flashcards and multiple choice questions, each question includes hints and explanations. Prepare to excel!

Multiple Choice

Which hypersensitivity type is involved in myasthenia gravis?

Explanation:
Myasthenia gravis involves autoantibodies directed against a component on the surface of the neuromuscular junction, most often the acetylcholine receptor. These antibodies bind to the receptor, blocking acetylcholine signaling, promoting receptor internalization, and can activate complement to damage the postsynaptic membrane. The result is impaired transmission at the neuromuscular junction and fatigable weakness. This is the hallmark of an antibody-mediated process acting on cell-surface structures, which defines Type II hypersensitivity. Other mechanisms in immunology differ in their usual patterns: Type I is IgE-driven allergic reactions, Type III involves immune complex deposition, and Type IV is T-cell–mediated delayed-type hypersensitivity. So the hypersensitivity type involved here is antibody-mediated cytotoxic or antibody-mediated dysfunction targeting a cell-surface receptor—Type II.

Myasthenia gravis involves autoantibodies directed against a component on the surface of the neuromuscular junction, most often the acetylcholine receptor. These antibodies bind to the receptor, blocking acetylcholine signaling, promoting receptor internalization, and can activate complement to damage the postsynaptic membrane. The result is impaired transmission at the neuromuscular junction and fatigable weakness. This is the hallmark of an antibody-mediated process acting on cell-surface structures, which defines Type II hypersensitivity.

Other mechanisms in immunology differ in their usual patterns: Type I is IgE-driven allergic reactions, Type III involves immune complex deposition, and Type IV is T-cell–mediated delayed-type hypersensitivity. So the hypersensitivity type involved here is antibody-mediated cytotoxic or antibody-mediated dysfunction targeting a cell-surface receptor—Type II.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy